Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOACT trial of endovascular thrombolysis versus heparin for severe cerebral venous thrombosis
NL-OMON34537Phase 2Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Sep 2011
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tissue-plasminogen activator, urokinase and heparin in cerebral sinovenous thrombosis (CSVT) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Primary efficacy endpoint. Started Sep 2011; status: active, not recruiting.
02
Drugs
tissue-plasminogen activatorurokinaseheparin
03
Conditions
cerebral sinovenous thrombosis (CSVT)
Beyond the preview
Go deeper on NL-OMON34537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34537.